#immunotherapy

Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.

Imjudo plus Imfinzi improved overall survival compared with standard targeted therapy for hepatocellular carcinoma.

Three checkpoint inhibitors reduce the risk of death for patients with hard-to-treat liver and biliary tract cancers.

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.

Sintilimab plus chemotherapy infused into a liver artery may offer the chance for a cure.

Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.

Stivarga also improved survival in those with recurrent HCC after a liver transplant.

Nearly half of patients treated with the combination saw their tumors shrink in an early study.

The immunotherapy and targeted therapy combo improved both overall survival and patient-reported outcomes.

A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.

Tecentriq plus Avastin improved improved overall survival and patient experiences during treatment.

Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.

Immunotherapy did not improve overall survival but led to fewer side effects and better quality of life.

Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.

Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.